We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App





New Portable PCR COVID-19 Test Kit from Visby Medical Secures FDA Emergency Use Authorization

By LabMedica International staff writers
Posted on 18 Sep 2020
A new portable PCR COVID-19 test kit has been granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for use in lab environments.

Visby Medical (San Jose, CA, USA), a Silicon Valley startup, has become the first company to be granted FDA EUA for a portable PCR COVID-19 test kit, which it has named Personal PCR. More...
Since the last seven years, Adam de la Zerda, the founder and CEO of Visby, has been working on shrinking the traditional PCR testing machine which is the size of a large microwave to a portable size that would fit in the palm. By bringing the power of the lab in the palm of the hand, the portable Personal PCR has the potential to be used by anyone, anywhere.

A sample taken via a nasal swab is inserted into the kit which features LED lights that indicate the test is running and alerts when it is completed. Visby’s portable Personal PCR test goes anywhere to deliver the serious infection result needed in less than 30 minutes. The single-use test with less than two minutes of hands-on time is easy to use, and delivers fast and accurate result right at the point of need. Visby’s Personal PCR is currently limited to lab use, although the company’s ultimate goal is to make the test available over the counter to anyone, anywhere at an affordable price.

“With our device you get the results you need while you’re still face to face with the patient, helping you make better and more timely decisions,” said Dr. Gary Schoolnik, Chief Medical Officer, Visby Medical.

“PCR, when appropriately applied, generates a highly sensitive and precise result. Visby’s PCR technology is so sensitive that it will pick up a signal that is likely to otherwise be missed,” said Dr. Shlomo Melmed, Executive Vice President of Academic Affairs, and Dean of the Medical Faculty and Professor of Medicine, Cedars-Sinai. “They have miniaturized PCR, validating it in the most rigorous fashion that satisfies both the compliance agencies as well as practicing physicians. This is a very important patient-friendly advance which will lead to a new class of point of care diagnostics.”

“The COVID-19 pandemic has highlighted the vital importance of very accurate, quick-response, single-use tests. With them, lives can return to normal both in developed and developing countries without causing numerous casualties,” said Sir Ronald Cohen, preeminent international philanthropist, venture capitalist, private equity investor and social innovator. “Visby’s team has shown how brilliant entrepreneurship can bring groundbreaking innovation in testing, not just for COVID-19, but for all infectious diseases, now and in the future.”

Related Links:
Visby Medical


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Biochemical Analyzer
iBC 900
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.